Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy
Author(s) -
So Yun Lee,
Moon Sung Kang,
Woo Yeup Jeong,
DongWook Han,
Ki Su Kim
Publication year - 2020
Publication title -
cancers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.818
H-Index - 76
ISSN - 2072-6694
DOI - 10.3390/cancers12040940
Subject(s) - hyaluronic acid , biocompatibility , immunogenicity , drug delivery , liposome , nanomedicine , cancer therapy , self healing hydrogels , chemistry , nanotechnology , cancer , pharmacology , cancer research , nanoparticle , materials science , medicine , immune system , immunology , organic chemistry , anatomy
Hyaluronic acid (HA) is a natural mucopolysaccharide and has many useful advantages, including biocompatibility, non-immunogenicity, chemical versatility, non-toxicity, biodegradability, and high hydrophilicity. Numerous tumor cells overexpress several receptors that have a high binding affinity for HA, while these receptors are poorly expressed in normal body cells. HA-based drug delivery carriers can offer improved solubility and stability of anticancer drugs in biological environments and allow for the targeting of cancer treatments. Based on these benefits, HA has been widely investigated as a promising material for developing the advanced clinical cancer therapies in various formulations, including nanoparticles, micelles, liposomes, and hydrogels, combined with other materials. We describe various approaches and findings showing the feasibility of improvement in theragnosis probes through the application of HA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom